Guardian Pharmacy Services, Inc. (GRDN)
Guardian Pharmacy Services provides technology-enabled pharmacy solutions to long-term care facilities in the United States, focusing on lower acuity settings. Their services include clinical support, drug dispensing, and administration, all enhanced by data-driven insights.
Company Overview
Guardian Pharmacy Services delivers tailored pharmacy solutions to long-term care facilities, leveraging technology and data analytics to optimize medication management and clinical outcomes, positioning them as a key player in the evolving healthcare landscape with a P/E ratio of 50.75.
Investment Thesis
Guardian Pharmacy Services presents a compelling investment opportunity due to its strategic focus on the underserved market of lower acuity long-term care facilities. The company's technology-enabled solutions, including Guardian Compass and GuardianShield Programs, drive efficiency and improve clinical outcomes, enhancing its value proposition to LTCFs. With a market capitalization of $2.08 billion and a profit margin of 2.9%, Guardian Pharmacy Services demonstrates financial stability and growth potential. Key value drivers include the increasing demand for specialized pharmacy services in LTCFs, the company's ability to leverage data analytics to optimize operations, and its established presence in a fragmented market. Upcoming catalysts include potential expansion into new geographic markets and the development of innovative service offerings. The company's beta of 0.96 suggests lower volatility compared to the broader market, making it an attractive option for risk-averse investors.
Key Highlights
- Market capitalization of $2.08 billion reflects substantial investor confidence in Guardian Pharmacy Services' market position and growth prospects.
- P/E ratio of 50.75 indicates investor expectations for future earnings growth, driven by increasing demand for specialized pharmacy services.
- Gross margin of 19.7% demonstrates the company's ability to maintain profitability while delivering value-added services to long-term care facilities.
- A beta of 0.96 suggests the stock is slightly less volatile than the market, offering a degree of stability in investment portfolios.
- The company's focus on technology-enabled solutions, such as Guardian Compass, differentiates it from competitors and enhances its operational efficiency.
Competitors
Strengths
- Technology-enabled solutions enhance efficiency and improve clinical outcomes.
- Focus on lower acuity LTCFs allows for specialized service offerings.
- Established relationships with LTCF operators provide a stable customer base.
- Data-driven insights enable continuous improvement and optimization.
Weaknesses
- Reliance on LTCF reimbursement models exposes the company to regulatory risks.
- Limited geographic diversification may constrain growth potential.
- Profit margin of 2.9% is relatively low compared to industry peers.
- High P/E ratio of 50.75 suggests the stock may be overvalued.
Catalysts
- Upcoming: Potential acquisitions of smaller pharmacy providers to expand market share.
- Ongoing: Increasing demand for specialized pharmacy services in LTCFs due to the aging population.
- Ongoing: Continued adoption of technology-enabled solutions by LTCFs to improve efficiency and reduce costs.
- Upcoming: Development and launch of new service offerings, such as specialized medication management programs.
Risks
- Potential: Changes in government regulations and reimbursement policies could negatively impact revenue.
- Potential: Economic downturns may reduce occupancy rates in LTCFs, leading to lower demand for pharmacy services.
- Ongoing: Increasing competition from larger pharmacy chains and specialized providers.
- Potential: Cybersecurity threats and data breaches could compromise patient information and damage the company's reputation.
Growth Opportunities
- Expansion into new geographic markets represents a significant growth opportunity for Guardian Pharmacy Services. By extending its reach beyond its current footprint, the company can tap into underserved markets and increase its customer base. The market size for LTC pharmacy services is estimated at over $20 billion annually, providing ample room for growth. This expansion can be achieved through strategic acquisitions or organic growth, with a timeline of 3-5 years for significant market penetration. The company's established infrastructure and expertise in serving LTCFs provide a competitive advantage in entering new regions.
- Development of innovative service offerings, such as specialized medication management programs for specific conditions (e.g., dementia, diabetes), can drive revenue growth and enhance customer loyalty. The market for specialized pharmacy services is growing rapidly, with a projected annual growth rate of 8-10%. Guardian Pharmacy Services can leverage its data analytics capabilities to identify unmet needs and develop tailored solutions. This initiative can be implemented within 1-2 years, with ongoing refinement and expansion based on market feedback. The company's clinical expertise and technology platform provide a strong foundation for innovation.
- Strategic partnerships with LTCF operators can create synergistic opportunities and drive customer acquisition. By collaborating with leading LTCF chains, Guardian Pharmacy Services can gain access to a large pool of potential customers and streamline its sales and marketing efforts. The market for LTCF services is highly fragmented, with numerous regional and national operators. These partnerships can be established within 6-12 months, with ongoing collaboration to optimize service delivery and enhance customer satisfaction. The company's reputation for quality and reliability makes it an attractive partner for LTCF operators.
- Leveraging data analytics to improve medication adherence and reduce healthcare costs can create value for both LTCFs and payers. By identifying patients at risk of non-adherence and implementing targeted interventions, Guardian Pharmacy Services can improve clinical outcomes and reduce hospital readmissions. The market for medication adherence solutions is growing rapidly, driven by the increasing focus on value-based care. This initiative can be implemented within 1-2 years, with ongoing monitoring and refinement based on patient outcomes. The company's data analytics platform and clinical expertise provide a competitive advantage in this area.
- Expanding into the specialty pharmacy market for LTCFs represents a high-growth opportunity. Specialty medications, such as biologics and infused therapies, are increasingly used in LTCFs to treat complex conditions. The market for specialty pharmacy services is growing at a double-digit rate, driven by the increasing prevalence of chronic diseases and the availability of new therapies. Guardian Pharmacy Services can leverage its existing infrastructure and expertise to enter this market, with a timeline of 2-3 years for significant market penetration. The company's focus on technology and data analytics will be critical for managing the complexities of specialty pharmacy.
Opportunities
- Expansion into new geographic markets can drive revenue growth.
- Development of innovative service offerings can enhance customer loyalty.
- Strategic partnerships with LTCF operators can create synergistic opportunities.
- Leveraging data analytics to improve medication adherence can reduce healthcare costs.
Threats
- Increasing competition from larger pharmacy chains and specialized providers.
- Changes in government regulations and reimbursement policies.
- Economic downturns may reduce occupancy rates in LTCFs.
- Cybersecurity threats and data breaches could compromise patient information.
Competitive Advantages
- Specialized Focus: Concentrating on lower acuity LTCFs allows for tailored service offerings and deeper market penetration.
- Technology-Enabled Solutions: Guardian Compass and GuardianShield Programs provide a competitive edge through data-driven insights and enhanced safety protocols.
- Established Relationships: Long-standing partnerships with LTCFs create a stable revenue stream and barriers to entry for new competitors.
- Scalable Infrastructure: The company's infrastructure is designed to efficiently serve a growing number of LTCFs across multiple geographic locations.
About
Founded in 2003 and headquartered in Atlanta, Georgia, Guardian Pharmacy Services, Inc. emerged to address the unique pharmaceutical needs of residents in long-term health care facilities (LTCFs). Recognizing the increasing demand for specialized pharmacy services within this sector, the company developed a comprehensive suite of technology-enabled solutions designed to improve medication management and clinical outcomes. Guardian Pharmacy Services primarily caters to lower acuity LTCFs, including assisted living facilities, behavioral health facilities, and group homes. Their core offerings encompass individualized clinical support, precise drug dispensing, and efficient administration capabilities, all tailored to the specific requirements of each facility and its residents. A key differentiator is Guardian Compass, a proprietary platform that utilizes data from the company's data warehouse to provide local pharmacies with actionable insights for business planning, tracking, and optimization. Complementing this is the GuardianShield Programs, designed to enhance safety and compliance within LTCFs. With 3,400 employees, Guardian Pharmacy Services has established a significant presence in the US market, providing a vital link between pharmaceutical care and the well-being of vulnerable populations within long-term care settings. The company's commitment to innovation and data-driven solutions positions it as a leader in the evolving landscape of specialized pharmacy services.
What They Do
- Provide technology-enabled pharmacy services to long-term care facilities (LTCFs).
- Offer individualized clinical support to residents in LTCFs.
- Dispense medications accurately and efficiently.
- Administer medications according to prescribed regimens.
- Serve residents in lower acuity LTCFs, such as assisted living facilities.
- Utilize Guardian Compass for data-driven business planning and optimization.
- Implement GuardianShield Programs to enhance safety and compliance in LTCFs.
Business Model
- Generate revenue through the dispensing of prescription medications to residents in LTCFs.
- Provide clinical consulting services to LTCFs, optimizing medication management and patient care.
- Offer technology solutions, such as Guardian Compass, to enhance operational efficiency for LTCFs.
- Establish contracts with LTCFs to provide comprehensive pharmacy services.
Industry Context
Guardian Pharmacy Services operates within the medical distribution industry, a segment of the healthcare sector experiencing steady growth due to the aging population and increasing demand for long-term care services. The market is characterized by a mix of large national players and smaller regional providers. Guardian Pharmacy Services distinguishes itself through its focus on lower acuity LTCFs and its technology-driven approach. The industry is subject to regulatory scrutiny and evolving reimbursement models, requiring companies to adapt and innovate to maintain profitability. The company's commitment to data analytics and customized solutions positions it favorably within this competitive landscape, allowing it to capture market share and drive growth.
Key Customers
- Assisted living facilities (ALFs)
- Behavioral health facilities
- Group homes
- Other lower acuity long-term care facilities
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $377M | $10M | $0.00 |
| Q2 2025 | $344M | $9M | $0.00 |
| Q1 2025 | $329M | $9M | $0.00 |
| Q4 2024 | $339M | $12M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Guardian Pharmacy Services, Inc. (GRDN) stock price: $31.18 (+1.65, +5.59%)
Why Bull
- •Recent insider buying suggests confidence in the company's future, indicating that leadership believes in the growth potential of Guardian Pharmacy Services.
- •Community sentiment has shifted positively, with discussions highlighting the company's robust service offerings and customer satisfaction.
- •Market perception is improving as the healthcare sector continues to expand, positioning Guardian favorably within a growing industry.
- •Analysts note that Guardian's strategic partnerships are enhancing its competitive edge, fostering optimism among investors.
Why Bear
- •Despite the positive sentiment, some community members express concerns about regulatory challenges facing the pharmacy industry, which could impact operations.
- •Recent discussions point to increased competition, with new entrants in the market potentially diluting Guardian's market share.
- •There are worries about the company’s dependency on certain revenue streams, making it vulnerable to shifts in healthcare policies.
- •Some analysts caution that the overall economic environment remains uncertain, which could affect consumer spending in the healthcare sector.
Latest News
-
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
Yahoo! Finance: GRDN News · Feb 12, 2026
-
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
Business Wire · Feb 12, 2026
-
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
businesswire.com · Feb 12, 2026
-
Guardian Pharmacy Services, Inc., to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call
Yahoo! Finance: GRDN News · Feb 9, 2026
Technical Analysis
Rationale
AI-generated technical analysis for GRDN including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Guardian Pharmacy Services, Inc. (GRDN) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for GRDN.
Make a Prediction
Set your price target for Guardian Pharmacy Services, Inc. (GRDN), choose a timeframe, and track your prediction accuracy.
Current price: $31.18
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRDN.
Price Targets
Wall Street price target analysis for GRDN.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 17.4% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 3/100
Gross margin of 19.7% is below average, suggesting thin margins and potential pricing pressure.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates GRDN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
Guardian Pharmacy Services, Inc., to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call
Frequently Asked Questions
What does Guardian Pharmacy Services, Inc. do?
Guardian Pharmacy Services, Inc. provides comprehensive pharmacy solutions tailored for residents in long-term care facilities (LTCFs) across the United States. They specialize in serving lower acuity LTCFs, such as assisted living and behavioral health facilities, offering individualized clinical support, precise drug dispensing, and efficient medication administration. Their proprietary technology, including Guardian Compass, leverages data analytics to optimize pharmacy operations and enhance patient care. By focusing on this niche market and providing technology-driven solutions, Guardian Pharmacy Services aims to improve medication management and clinical outcomes for vulnerable populations in long-term care settings.
Is GRDN stock a good buy?
GRDN stock presents a mixed investment profile. The company's focus on the growing LTCF market and its technology-enabled solutions offer significant growth potential. However, the high P/E ratio of 50.75 suggests that the stock may be overvalued, and the relatively low profit margin of 2.9% warrants careful consideration. Investors should weigh the company's growth prospects against its valuation and potential risks, such as regulatory changes and increasing competition. A thorough analysis of the company's financial performance and market position is essential before making an investment decision. The absence of a dividend yield may deter some investors.
What are the main risks for GRDN?
Guardian Pharmacy Services faces several key risks. Changes in government regulations and reimbursement policies for LTCFs could significantly impact revenue. Increasing competition from larger pharmacy chains and specialized providers may erode market share. Economic downturns could reduce occupancy rates in LTCFs, leading to lower demand for pharmacy services. Additionally, cybersecurity threats and data breaches pose a significant risk to patient information and the company's reputation. Investors should carefully consider these potential risks before investing in GRDN stock.
Is GRDN a good stock to buy?
Whether GRDN is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the GRDN MoonshotScore?
The MoonshotScore for GRDN is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is GRDN data updated?
GRDN stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to GRDN is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for GRDN?
Growth catalysts for Guardian Pharmacy Services, Inc. (GRDN) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Guardian Pharmacy Services, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are GRDN's main competitors?
Guardian Pharmacy Services, Inc. (GRDN) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether GRDN has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about GRDN?
Wall Street analyst coverage for GRDN includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is GRDN's market cap?
Market capitalization (market cap) for GRDN is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows GRDN's current market cap alongside enterprise value and other valuation metrics.
How has GRDN stock performed recently?
GRDN's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing GRDN's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in GRDN?
Key risk categories for GRDN include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures GRDN's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling GRDN?
Insider trading activity for GRDN tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is GRDN a good stock for beginners?
Guardian Pharmacy Services, Inc. (GRDN) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is GRDN for first-time investors?
Every stock carries risk, including Guardian Pharmacy Services, Inc. (GRDN). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like GRDN.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- Market analysis is based on current industry trends and may not accurately predict future outcomes.
- This dossier is for informational purposes only and does not constitute investment advice.